These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16186242)

  • 1. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
    Repits J; Öberg M; Esbjörnsson J; Medstrand P; Karlsson A; Albert J; Fenyö EM; Jansson M
    J Gen Virol; 2005 Oct; 86(Pt 10):2859-2869. PubMed ID: 16186242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    Reeves JD; Miamidian JL; Biscone MJ; Lee FH; Ahmad N; Pierson TC; Doms RW
    J Virol; 2004 May; 78(10):5476-85. PubMed ID: 15113926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
    Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
    J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.
    Borggren M; Repits J; Kuylenstierna C; Sterjovski J; Churchill MJ; Purcell DF; Karlsson A; Albert J; Gorry PR; Jansson M
    Retrovirology; 2008 Mar; 5():28. PubMed ID: 18371209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.
    Karlsson I; Antonsson L; Shi Y; Oberg M; Karlsson A; Albert J; Olde B; Owman C; Jansson M; Fenyö EM
    J Virol; 2004 Nov; 78(21):11807-15. PubMed ID: 15479822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors.
    Koning FA; Koevoets C; van der Vorst TJ; Schuitemaker H
    Antivir Ther; 2005; 10(2):231-7. PubMed ID: 15865217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.
    Gray L; Sterjovski J; Churchill M; Ellery P; Nasr N; Lewin SR; Crowe SM; Wesselingh SL; Cunningham AL; Gorry PR
    Virology; 2005 Jul; 337(2):384-98. PubMed ID: 15916792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.
    Karlsson U; Antonsson L; Repits J; Medstrand P; Owman C; Kidd-Ljunggren K; Hagberg L; Svennerholm B; Jansson M; Gisslén M; Ljungberg B
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1297-1305. PubMed ID: 20001314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.
    Lobritz MA; Marozsan AJ; Troyer RM; Arts EJ
    J Virol; 2007 Aug; 81(15):8258-69. PubMed ID: 17522224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
    Heredia A; Gilliam B; DeVico A; Le N; Bamba D; Flinko R; Lewis G; Gallo RC; Redfield RR
    AIDS; 2007 Jun; 21(10):1317-22. PubMed ID: 17545708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
    Ketas TJ; Klasse PJ; Spenlehauer C; Nesin M; Frank I; Pope M; Strizki JM; Reyes GR; Baroudy BM; Moore JP
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):177-86. PubMed ID: 12689409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
    Rusert P; Kuster H; Joos B; Misselwitz B; Gujer C; Leemann C; Fischer M; Stiegler G; Katinger H; Olson WC; Weber R; Aceto L; Günthard HF; Trkola A
    J Virol; 2005 Jul; 79(13):8454-69. PubMed ID: 15956589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.